BackgroundHealthcare-associated infections (HAIs) have a major impact on public health worldwide. Particularly, hospital surfaces contaminated with bacterial pathogens are often the origin of both sporadic cases and outbreaks of HAIs. It has been demonstrated that copper surfaces reduce the microbial burden of high touch surfaces in the hospital environment. Here we report the antimicrobial characterization of a novel composite coating with embedded copper particles, named Copper Armour™.MethodsThe Copper Armour™ bactericidal activity was evaluated in in vitro assays against several bacterial pathogens, including Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli O157:H7 and Listeria monocytogenes. Additionally, its antimicrobial properties were also evaluated in a pilot study over a nine-week period at an adult intensive care unit. For this, four high touch surfaces, including bed rails, overbed table, bedside table and IV Pole, were coated with Cooper Armour™, and its microbial burden was determined over a nine-week period.ResultsCopper Armour™ coated samples showed an in vitro reduction in bacterial burden of > 99.9% compared to control samples. Moreover, pilot study results indicate that Copper Armour™ significantly reduces the level of microbial contamination on high-touch surfaces in the hospital environment, as compared with standard surfaces.ConclusionsBased on its antimicrobial properties, Copper Armour™ is a novel self-sanitizing coating that exhibits bactericidal activity against important human pathogens and significantly reduces the microbial burden of hospital surfaces. This composite could be used as a self-sanitizing coating to complement infection control strategies in healthcare facilities.
ObjectiveTo evaluate the efficacy and safety of percutaneous tracheostomy by means of
single-step dilation with fiber optic bronchoscopy assistance in critical care
patients under mechanical ventilation.MethodsBetween the years 2004 and 2014, 512 patients with indication of tracheostomy
according to clinical criteria, were prospectively and consecutively included in
our study. One-third of them were high-risk patients. Demographic variables,
APACHE II score, and days on mechanical ventilation prior to percutaneous
tracheostomy were recorded. The efficacy of the procedure was evaluated according
to an execution success rate and based on the necessity of switching to an open
surgical technique. Safety was evaluated according to post-operative and operative
complication rates.ResultsThe mean age of the group was 64 ± 18 years (203 women and 309 males). The
mean APACHE II score was 21 ± 3. Patients remained an average of 11
± 3 days on mechanical ventilation before percutaneous tracheostomy was
performed. All procedures were successfully completed without the need to switch
to an open surgical technique. Eighteen patients (3.5%) presented procedure
complications. Five patients experienced transient desaturation, 4 presented low
blood pressure related to sedation, and 9 presented minor bleeding, but none
required a transfusion. No serious complications or deaths associated with the
procedure were recorded. Eleven patients (2.1%) presented post-operative
complications. Seven presented minor and transitory bleeding of the percutaneous
tracheostomy stoma, 2 suffered displacement of the tracheostomy cannula, and 2
developed a superficial infection of the stoma.ConclusionPercutaneous tracheostomy using the single-step dilation technique with fiber
optic bronchoscopy assistance seems to be effective and safe in critically ill
patients under mechanical ventilation when performed by experienced intensive care
specialists using a standardized procedure.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.